Market Research Logo

Von Willebrand Disease (VWD)- Epidemiology Forecast to 2027

DelveInsight’s ‘Von Willebrand Disease (VWD)- Epidemiology Forecast to 2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Von Willebrand Disease in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan

Study Period: 2016-2027

Von Willebrand Disease Epidemiology
The Von Willebrand Disease (VWD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Von Willebrand Disease are studied through all possible divisions to give a better understanding about the disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
Von Willebrand Disease Epidemiology Segmentation
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total diagnosed prevalent cases, sex- specific diagnosed prevalent cases, type specific diagnosed prevalent cases and age specific diagnosed prevalent cases) scenario of Von Willebrand Disease (VWD) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
According to DelveInsight, the total number of diagnosed prevalent population of Von Willebrand Disease (VWD) was found to be 35,396, in the year 2016.

Report Scope
• The report covers detailed overview of Von Willebrand Disease explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The report provides the insight about the historical and forecasted patient pool of Von Willebrand Disease in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Report assesses the disease risk and burden and highlights the unmet needs of the disease
• The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report provides the segmentation of the disease epidemiology by sub-type i.e., Type 1, 2 and 3 VWD in 7MM.

Key strengths
• 10 Year Forecast of Von Willebrand Disease epidemiology
• 7MM Coverage
• Total Diagnosed Prevalent Cases of VWD
• Diagnosed Prevalent Cases according to segmentation: Subtype-specific, Age specific and Gender specific

Key assessments
• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population


1. Key Insights
2. Disease Background and Overview: von Willebrand Disease (vWD)
2.1. Introduction
2.2. Classification
2.3. Clinical Manifestations
2.4. Pathophysiology
2.5. Diagnosis
3. Epidemiology and Patient Population
3.1. Key Findings
4. 7MM Total Diagnosed Prevalent Patient Population of von Willebrand Disease
5. Country Wise-Epidemiology of von Willebrand Disease
5.1. United States
5.1.1. Total Diagnosed Prevalent Population of von Willebrand Disease in the US
5.1.2. Sex-Specific Diagnosed Prevalent Population of von Willebrand Disease in the US
5.1.3. Type Specific Diagnosed Prevalent Population of Von Willebrand Disease in the US
5.1.4. Age Specific Diagnosed Prevalent Population of von Willebrand Disease in the US
5.2. EU5 Countries
5.3. Germany
5.3.1. Total Diagnosed Prevalent Population of von Willebrand Disease in Germany
5.3.2. Sex-Specific Diagnosed Prevalent Population of Von Willebrand Disease in Germany
5.3.3. Type Specific Diagnosed Prevalence of von Willebrand Disease in Germany
5.3.4. Age Specific Diagnosed Prevalent Population of Von Willebrand Disease in Germany
5.4. France
5.4.1. Total Diagnosed Prevalent Population of Von Willebrand Disease in France
5.4.2. Sex-Specific Diagnosed Prevalent Population of von Willebrand Disease in France
5.4.3. Type Specific Diagnosed Prevalence of Von Willebrand Disease in France
5.4.4. Age Specific Diagnosed Prevalent Population of Von Willebrand Disease in France
5.5. Italy
5.5.1. Total Diagnosed Prevalent Population of von Willebrand Disease in Italy
5.5.2. Sex-Specific Diagnosed Prevalent Population of Von Willebrand Disease in Italy
5.5.3. Type Specific Diagnosed Prevalence of von Willebrand Disease in Italy
5.5.4. Age Specific Diagnosed Prevalent Population of von Willebrand Disease in Italy
5.6. Spain
5.6.1. Total Diagnosed Prevalent Population of Von Willebrand Disease in Spain
5.6.2. Sex-Specific Diagnosed Prevalent Population of von Willebrand Disease in Spain
5.6.3. Type Specific Diagnosed Prevalence of Von Willebrand Disease in Spain
5.6.4. Age Specific Diagnosed Prevalent Population of von Willebrand Disease in Spain
5.7. United Kingdom
5.7.1. Total Diagnosed Prevalent Population of von Willebrand Disease in the United Kingdom
5.7.2. Sex-Specific Diagnosed Prevalent Population of von Willebrand Disease in the United Kingdom
5.7.3. Type Specific Diagnosed Prevalence of Von Willebrand Disease in the United Kingdom
5.7.4. Age Specific Diagnosed Prevalent Population of von Willebrand Disease in the United Kingdom
5.8. Japan
5.8.1. Total Diagnosed Prevalent Population of von Willebrand Disease in Japan
5.8.2. Sex-Specific Diagnosed Prevalent Population of Von Willebrand Disease in Japan
5.8.3. Type Specific Diagnosed Prevalence of Von Willebrand Disease in Japan
5.8.4. Age Specific Diagnosed Prevalent Population of von Willebrand Disease in Japan
6. Appendix
6.1. Report Methodology
7. DelveInsight Capabilities
8. Disclaimer
9. About DelveInsight
List of Tables and Figures
Figure 1: The structure of VWF
Figure 2: Biosynthesis and Function of von Willebrand Factor
Figure 3: The role of von Willebrand factor (VWF) in hemostasis.
Figure 4: Type 2 VWD Variants.
Figure 5: Pathophysiological Mechanisms and Classification of von Willebrand Disease
Figure 6: Initial hemostasis laboratory evaluation
Figure 7: Algorithm proposed for the diagnosis and classification of VWD
Figure 8: Comparison of the multimeric structure of plasma VWF from VWD patients and normal individuals. Low (A) and intermediate (B) resolution VWF multimer analysis
Figure 9: Total Diagnosed Prevalent Patient Population of Von Willebrand Disease in the 7MM (2016-2027)
Figure 10: Diagnosed Prevalence of Von Willebrand Disease in the United States (2016-2027)
Figure 11: Sex Specific Diagnosed Prevalence of Von Willebrand Disease in the United States (2016-2027)
Figure 12: Type Specific Diagnosed Prevalence of Von Willebrand Disease in the United States (2016-2027)
Figure 13: Age Specific Diagnosed Prevalence of Von Willebrand Disease in the United States (2016-2027)
Figure 14: Total Diagnosed Prevalent Population of Von Willebrand Disease in Germany (2016-2027)
Figure 15: Sex Specific Diagnosed Prevalence of Von Willebrand Disease in Germany (2016-2027)
Figure 16: Type Specific Diagnosed Prevalence of Von Willebrand Disease in Germany (2016-2027)
Figure 17: Age Specific Diagnosed Prevalence of Von Willebrand Disease in Germany (2016-2027)
Figure 18: Total Diagnosed Prevalent Population of Von Willebrand Disease in France (2016-2027)
Figure 19: Sex Specific Diagnosed Prevalence of Von Willebrand Disease in France (2016-2027)
Figure 20: Type Specific Diagnosed Prevalence of Von Willebrand Disease in France (2016-2027)
Figure 21: Age Specific Diagnosed Prevalence of Von Willebrand Disease in France (2016-2027)
Figure 22: Total Diagnosed Prevalent Population of Von Willebrand Disease in Italy (2016-2027)
Figure 23: Sex Specific Diagnosed Prevalence of Von Willebrand Disease in Italy (2016-2027)
Figure 24: Type Specific Diagnosed Prevalence of Von Willebrand Disease in Italy (2016-2027)
Figure 25: Age Specific Diagnosed Prevalence of Von Willebrand Disease in Italy (2016-2027)
Figure 26: Total Diagnosed Prevalent Population of Von Willebrand Disease in Spain (2016-2027)
Figure 27: Sex Specific Diagnosed Prevalence of Von Willebrand Disease in Spain (2016-2027)
Figure 28: Type Specific Diagnosed Prevalence of Von Willebrand Disease in Spain (2016-2027)
Figure 29: Age Specific Diagnosed Prevalence of Von Willebrand Disease in Spain (2016-2027)
Figure 30: Total Diagnosed Prevalent Population of Von Willebrand Disease in the UK (2016-2027)
Figure 31: Sex Specific Diagnosed Prevalence of Von Willebrand Disease in the UK (2016-2027)
Figure 32: Type Specific Diagnosed Prevalence of Von Willebrand Disease in the UK (2016-2027)
Figure 33: Age Specific Diagnosed Prevalence of Von Willebrand Disease in the UK (2016-2027)
Figure 34: Total Diagnosed Prevalent Population of Von Willebrand Disease in Japan (2016-2027)
Figure 35: Sex Specific Diagnosed Prevalence of Von Willebrand Disease in Japan (2016-2027)
Figure 36: Type Specific Diagnosed Prevalence of Von Willebrand Disease in Japan (2016-2027)
Figure 37: Age Specific Diagnosed Prevalence of Von Willebrand Disease in Japan (2016-2027)
List of Tables and Figures
Table 1: Classification of von Willebrand disease
Table 2: Sub-Classification of von Willebrand disease Type 2A
Table 3: Total Diagnosed Prevalent Population of Von Willebrand Disease in the 7MM (2016-2027)
Table 4: Total Diagnosed Prevalent Population of Von Willebrand Disease in the US (2016-2027)
Table 5: Sex Specific Diagnosed Prevalence of Von Willebrand Disease in the US (2016-2027)
Table 6: Type Specific Diagnosed Prevalence of Von Willebrand Disease in the US (2016-2027)
Table 7: Age Specific Diagnosed Prevalence of Von Willebrand Disease in the US (2016-2027)
Table 8: Total Diagnosed Prevalent Population of Von Willebrand Disease in Germany (2016-2027)
Table 9: Sex Specific Diagnosed Prevalence of Von Willebrand Disease in Germany (2016-2027)
Table 10: Type Specific Diagnosed Prevalence of Von Willebrand Disease in Germany (2016-2027)
Table 11: Age Specific Diagnosed Prevalence of Von Willebrand Disease in Germany (2016-2027)
Table 12: Total Diagnosed Prevalent Population of Von Willebrand Disease in France (2016-2027)
Table 13: Sex Specific Diagnosed Prevalence of Von Willebrand Disease in France (2016-2027)
Table 14: Type Specific Diagnosed Prevalence of Von Willebrand Disease in France (2016-2027)
Table 15: Age Specific Diagnosed Prevalence of Von Willebrand Disease in France (2016-2027)
Table 16: Total Diagnosed Prevalent Population of Von Willebrand Disease in Italy (2016-2027)
Table 17: Sex Specific Diagnosed Prevalence of Von Willebrand Disease in Italy (2016-2027)
Table 18: Type Specific Diagnosed Prevalence of Von Willebrand Disease in Italy (2016-2027)
Table 19: Age Specific Diagnosed Prevalence of Von Willebrand Disease in Italy (2016-2027)
Table 20: Total Diagnosed Prevalent Population of Von Willebrand Disease in Spain (2016-2027)
Table 21: Sex Specific Diagnosed Prevalence of Von Willebrand Disease in Spain (2016-2027)
Table 22: Type Specific Diagnosed Prevalence of Von Willebrand Disease in Spain (2016-2027)
Table 23: Age Specific Diagnosed Prevalence of Von Willebrand Disease in Spain (2016-2027)
Table 24: Total Diagnosed Prevalent Population of Von Willebrand Disease in the UK (2016-2027)
Table 25: Sex Specific Diagnosed Prevalence of Von Willebrand Disease in the UK (2016-2027)
Table 26: Type Specific Diagnosed Prevalence of Von Willebrand Disease in the UK (2016-2027)
Table 27: Age Specific Diagnosed Prevalence of Von Willebrand Disease in the UK (2016-2027)
Table 28: Total Diagnosed Prevalent Population of Von Willebrand Disease in Japan (2016-2027)
Table 29: Sex Specific Diagnosed Prevalence of Von Willebrand Disease in Japan (2016-2027)
Table 30: Type Specific Diagnosed Prevalence of Von Willebrand Disease in Japan (2016-2027)
Table 31: Age Specific Diagnosed Prevalence of Von Willebrand Disease in Japan (2016-2027)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report